Ioflupane (123i) Rotop

Ioflupane (123i), the active ingredient in Ioflupane (123i) Rotop, is a radiopharmaceutical presented as a solution for injection for intravenous use. It binds to presynaptic dopamine transporters, allowing single‑photon emission computed tomography (SPECT) imaging to assess dopaminergic neuronal integrity in patients with suspected Parkinsonian syndromes and related movement disorders.

GNH USA supplies Ioflupane (123i) Rotop as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide, providing EU‑approved batches for nuclear medicine departments across global markets.

Ioflupane (123i) is used in dopamine transporter imaging to evaluate patients with Parkinsonian and other movement disorders.

Parkinsonian syndromes: provides visual assessment of dopaminergic neuron loss to aid diagnosis. Movement disorder differential diagnosis: helps distinguish Parkinson's disease from essential tremor and other non‑degenerative tremor conditions. Neurodegenerative disease assessment: quantifies dopamine transporter availability for monitoring disease progression.

Adverse reactions may occur following intravenous administration of Ioflupane (123i).

Common Side Effects: - Nausea: mild to moderate feeling of stomach upset. - Headache: transient headache during or after injection. - Injection site pain: brief discomfort at the venipuncture site. - Dizziness: temporary light‑headedness. - Flushing: brief redness of the skin. - Mild hypotension: slight drop in blood pressure.

Serious or Rare Side Effects: - Anaphylaxis: severe allergic reaction requiring immediate medical attention. - Severe hypotension: marked drop in blood pressure causing faintness. - Pulmonary edema: fluid accumulation in the lungs. - Radiation‑related symptoms: rare excessive radiation exposure effects. - Seizures: uncommon neurologic event. - Severe skin reactions: such as Stevens‑Johnson syndrome.

Use of Ioflupane (123i) requires careful consideration of patient safety and handling requirements.

Pregnancy: avoid unless diagnostic benefit outweighs potential fetal radiation risk. Breastfeeding: contraindicated as the tracer may be secreted in breast milk. Renal impairment: adjust monitoring as reduced clearance may increase exposure. Known iodine‑123 hypersensitivity: do not administer to patients with documented allergy. Radiation safety: ensure administration by qualified nuclear medicine personnel with appropriate shielding. Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Ioflupane (123i) may interact with other substances that affect dopamine transporter binding or radiopharmaceutical distribution.

Major Interactions (Avoid): - Cocaine or amphetamines: compete for dopamine transporter sites and reduce imaging accuracy. - Methylphenidate: similar competition at the transporter level. - Bupropion: may alter tracer binding. - Nicotine products: can affect dopamine system and imaging results. - High‑dose dopamine agonists: may interfere with tracer uptake.

Moderate Interactions (Monitor Closely): - Other radiopharmaceuticals administered within 24 hours: cumulative radiation exposure. - Iodinated contrast agents: may affect iodine‑123 kinetics. - Antihypertensive drugs: monitor blood pressure due to potential additive hypotensive effect. - Sedatives or anxiolytics: may mask early adverse reactions. - Anticholinergic medications: could influence central nervous system imaging patterns.